IMBiologics
Latest round
- Series B
Last raised
- Jul 2023
Total raised
- $30M
Investors
- 16
About IMBiologics
IMBiologics, founded in 2020 in Suwon, South Korea, focuses on the development of immunomodulatory therapeutics.IMBiologics specializes in the research and development of innovative immunomodulatory antibody therapeutics aimed at restoring homeostasis in human health. The company’s flagship product, a bispecific antibody known as IMB-101 (NAV-240), targets both OX40L and TNFa, addressing inflammatory and autoimmune diseases such as hidradenitis suppurativa (HS), Crohn's disease, and ulcerative colitis. IMB-101 is designed to regulate inflammatory cytokines and adaptive immune responses, contributing to long-term immune balance.S. and Europe.IMBiologics operates through a model that encompasses licensing agreements and clinical trial partnerships, generating revenue from collaborations with other pharmaceutical companies and biotech firms. The structure of these transactions typically involves upfront licensing fees, milestone payments tied to clinical development achievements, and potential royalties based on product sales once market approval is obtained. For instance, the partnership with Navigator Medicines for IMB-101 is set to facilitate a Phase 1b clinical trial, suggesting a collaborative approach to advancing product development.S.
Who invested in IMBiologics
16 investors across 3 rounds
See all investors in IMBiologics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about IMBiologics
Who invested in IMBiologics?
IMBiologics has 16 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has IMBiologics raised?
IMBiologics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did IMBiologics last raise money?
IMBiologics's most recent round on record is a Series B, in Jul 2023.
What does IMBiologics do?
IMBiologics, founded in 2020 in Suwon, South Korea, focuses on the development of immunomodulatory therapeutics.
Where is IMBiologics headquartered?
IMBiologics is headquartered in Suwon-si, South Korea.
Which VCs invest in companies like IMBiologics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at IMBiologics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like IMBiologics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.